This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jeeninga, R. E. Articles by Berkhout, B. Search for Related Content PubMed PubMed Citation Articles by Jeeninga, R. E. Articles by Berkhout, B.

Construction of a Minimal HIV-1 Variant that Selectively Replicates in Leukemic Derived T-Cell Lines: Towards a New Virotherapy Approach

Departments of ¹ Human Retrovirology and ² Paediatric Oncology, Emma Children Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; and ³ Dutch Childhood Oncology Group, the Hague, the Netherlands

Requests for reprints: Ben Berkhout, Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands. Phone: 31-20-566-4822; Fax: 31-20-691-6531; E-mail: r.jeeninga{at}amc.uva.nl.

T-cell acute lymphoblastic leukemia is a high-risk type of blood-cell cancer. We analyzed the possibility of developing virotherapy for T-cell acute lymphoblastic leukemia. Virotherapy is based on the exclusive replication of a virus in leukemic cells, leading to the selective removal of these malignant cells. We constructed a minimized derivative of HIV-1, a complex lentivirus encoding multiple accessory functions that are essential for virus replication in untransformed cells, but dispensable in leukemic T cells. This mini-HIV virus has five deletions (vif, vpR, vpU, nef, and U3) and replicated in the SupT1 cell line, but did not replicate in normal peripheral blood mononuclear cells. The stripped down mini-HIV variant was also able to efficiently remove leukemic cells from a mixed culture with untransformed control cells. In contrast to wild-type HIV-1, we did not observe bystander killing in mixed culture experiments with the mini-HIV variant. Furthermore, viral escape was not detected in long-term cultures. The mini-HIV variant that uses CD4 and CXCR4 for cell entry could potentially be used against CXCR4-expressing malignancies such as T-lymphoblastic leukemia/lymphoma, natural killer leukemia, and some myeloid leukemias.

This article has been cited by other articles:

				I. Bontjer, A. Land, D. Eggink, E. Verkade, K. Tuin, C. Baldwin, G. Pollakis, W. A. Paxton, I. Braakman, B. Berkhout, et al. Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution J. Virol., January 1, 2009; 83(1): 368 - 383. [Abstract] [Full Text] [PDF]

				D. Eggink, C. E. Baldwin, Y. Deng, J. P. M. Langedijk, M. Lu, R. W. Sanders, and B. Berkhout Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants J. Virol., July 1, 2008; 82(13): 6678 - 6688. [Abstract] [Full Text] [PDF]

				X. Zhou, M. Vink, B. Klaver, K. Verhoef, G. Marzio, A. T. Das, and B. Berkhout The Genetic Stability of a Conditional Live HIV-1 Variant Can Be Improved by Mutations in the Tet-On Regulatory System That Restrain Evolution J. Biol. Chem., June 23, 2006; 281(25): 17084 - 17091. [Abstract] [Full Text] [PDF]